Characterization of the extent, the time course and the underlying pathomechanism of the elevated skin reactivity of chronic urticaria patients in comparison with healthy test subjects.

Characterization of the extent, the time course and the underlying pathomechanism of the elevated skin reactivity of chronic urticaria patients in comparison with healthy test subjects. - Skinsensitivity in chronic urticaria - SkisiCU

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012471

Enrollment

Registered

2017-05-31

Start date

2017-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L50.8

Interventions

Group 1: Patients with chronic urticaria will be evaluated for the extent and duration of weahl formation during routine-allergy-test including positive and negative controls. Repetitive objective mea

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: • Adults (18 years or older) • Able to read, understand and willing to sign the informed consent form and abide with study procedures • Willing, committed and able to complete all study-related procedures • Arm1: Diagnosis of urticaria for more than 6 weeks • Patients may have additional concomitant disease, but only one dominant skin disease. • No participation in other clinical trials 4 weeks before in this study

Exclusion criteria

Exclusion criteria: • Concurrent/ongoing treatment with immunosuppressives (e.g. cyclosporine, methotrexate, dapsone, systemic Corticosteroids or others) within 4 weeks or 5 half lives prior to study entry whichever is longer • Concurrent/ongoing treatment with Omomalizumab within 3 months prior to study entry • Prior or concurrent treatment with antihistamines within the last 5 days. • Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial • Lactating females or pregnant females • Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk • Intake of leukotriene antagonists within 7 days prior to study entry • History of hypersensitivity/allergy to local anesthetics

Design outcomes

Primary

Measure	Time frame
The size and the time course of inducible skin wheals in patients with chronic urticaria and healthy test subjects will be assessed via planimetry, volumetry and speckle-bloodflow analysis by repetetive non-invasive measurements over a time of about 2 hours.	—

Secondary

Measure	Time frame
Correlation of the wheal caracteristics with parameter of the histological analysis and serum parameter.	—

Countries

Germany

Contacts

Public ContactSabine Altrichter

Charite-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie

sabine.altrichter@charite.de+49-30-450518043

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026